Compare SLAB & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLAB | SYRE |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.5B |
| IPO Year | 2000 | 2015 |
| Metric | SLAB | SYRE |
|---|---|---|
| Price | $217.47 | $73.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $163.13 | $85.08 |
| AVG Volume (30 Days) | 335.3K | ★ 848.2K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.61 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $491,625,000.00 | N/A |
| Revenue This Year | $20.49 | N/A |
| Revenue Next Year | $16.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $115.51 | $13.93 |
| 52 Week High | $219.33 | $78.80 |
| Indicator | SLAB | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 61.06 | 55.17 |
| Support Level | $215.02 | $65.93 |
| Resistance Level | $218.68 | $76.16 |
| Average True Range (ATR) | 1.12 | 3.87 |
| MACD | -0.24 | -0.82 |
| Stochastic Oscillator | 66.82 | 56.86 |
Silicon Laboratories Inc Inc is a provider of secure, intelligent wireless technology for a more connected world. The company's integrated hardware and software platform, intuitive development tools, industry ecosystem, and robust support help customers build industrial, commercial, home, and life applications. Company make it easy for developers to solve complex wireless challenges throughout the product lifecycle and get to market quickly with solutions that transform industries, grow economies, and improve lives. Company operates in USA, China, Taiwan and Rest of World, with maximum revenue from rest of the world.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.